scholarly journals EVALUATION OF RESULTS OF WIDE RESECTION AND RECONSTRUCTION USING NON - VASCULARISED IPSILATERAL PROXIMAL FIBULA FOR GIANT CELL TUMOR OF LOWER END OF RADIUS

2015 ◽  
Vol 4 (53) ◽  
pp. 9186-9190
Author(s):  
Sujai S ◽  
Jayakrishnan S ◽  
Abhijeet Jayaswal ◽  
Siddalingaswamy M K ◽  
Venugopal N
Author(s):  
Pakjai Tuntarattanapong ◽  
Pongsiri Piakong ◽  
Thanapon Chobpenthai ◽  
Bhasanan Sukanthanak ◽  
Piya Kiatisevi

2021 ◽  
Author(s):  
taojun gong ◽  
Yi Luo ◽  
Yitian Wang ◽  
Chuanxi Zheng ◽  
Jianguo Fang ◽  
...  

Abstract Background: Giant cell tumor of bone (GCTB) is a rare benign but locally aggressive bone tumor. It has a high tendency for local recurrence, which may increase the occurrence of lung metastasis. Currently, the treatment of pulmonary metastases of GCTB is controversial. Denosumab is the preferred regimen for unresectable metastatic lesions, but there are no alternative treatment options when denosumab is resistant. So far, no case reports of metastatic GCTB treated with denosumab and apatinib have been published. Case presentation: This is a case report of a 26-year-old female who experienced right knee pain for over 6 months. Radiography and computed tomography revealed osteolytic bony destruction in the proximal right tibia. Using histological, radiological, and clinical techniques, a diagnosis of GCTB was achieved. Meanwhile, the immunohistochemical stain-identified the tumor cells were positive for vascular endothelial growth factor receptor 2 (VEGFR-2). After intralesional curettage of the primary tumor and wide resection of local recurrence surgeries, she developed recurrent hemoptysis. Chest computed tomography (CT) images showed multiple pulmonary nodules. She was administrated denosumab therapy but disease progression was confirmed after four months of treatment. She then received denosumab and apatinib therapy for 24 months, after a partial response was achieved.Conclusions: We depict a case of multiple pulmonary metastases of GCTB successfully controlled by denosumab and apatinib therapy. VEGFR-2 may be an effective therapeutic target for GCTB with pulmonary metastasis when denosumab is ineffective.


2020 ◽  
pp. 109352662096435
Author(s):  
Annie Orr ◽  
Huifei Liu ◽  
Rachel Mariani ◽  
Jennifer H Aldrink ◽  
Bhuvana A Setty ◽  
...  

We describe a rare pediatric case of a phalangeal giant cell tumor of bone with extensive bilateral lung metastases following curettage, wide resection, and amputation. Concurrent peripheral blood eosinophilia and pleural effusion with marked eosinophilia (47%) were present. To discover genetic changes driving tumor metastasis, genomic and transcriptome profiling of the metastatic lung mass as well as germline analysis were performed. Whole exome sequencing detected a histone H3F3A p.G35V missense mutation in tumor cells. RNA sequencing revealed overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL). The patient is alive with no residual disease and uncompromised respiratory function 29 months after amputation of primary tumor and 19 months after surgical resection of his metastatic lung disease.


2020 ◽  
Vol 4 (1) ◽  
pp. 64-67
Author(s):  
Sushil Adhikari ◽  
Arun Sigdel ◽  
Rajesh Kumar Sah ◽  
Luna Devkota

Giant cell tumour (GCT) is histopathologically benign tumor of long bone particularly in distal femur and the proximal tibia. It commonly occurs in adults of age 20-40 years but rare in children. GCT is considered to be locally aggressive tumor and tendency of recurrence is higher even after surgery. The clinical features are nonspecific, the principle symptoms are pain, swelling and limiting adjacent joint movements. Diagnosis is based on the radiographic appearance and histopathological findings .In our case X-ray showed ill defined lytic lesion on proximal fibula with cortical thinning and MRI finding revealed expansile lyticlesion in meta-epiphysis of right fibula 16×16×28mm adjacent to growth plate with fluid level. The sclerotic rim appears hypo intense on T1 & hyper intense on T2. Core needle biopsy showed giant cell tumor on proximal fibula. Considering the risk of recurrence wide local excision was done. Management of GCT of proximal fibula in young patient is critical for preventing recurrence and enhancing functional outcomes by saving adjacent anatomical structure. No evidence of local recurrence and metastasis was found in 24 months of follow up.


Author(s):  
Hosein Faezypour ◽  
Aileen M. Davis ◽  
Anthony M. Griffin ◽  
Robert S. Bell

2019 ◽  
Vol 2019 (9) ◽  
Author(s):  
Akio Sakamoto ◽  
Takeshi Okamoto ◽  
Shuichi Matsuda

Abstract Giant cell tumor of bone (GCTB) is a locally aggressive tumor. En bloc resection to reduce the recurrence rate has a high risk of peroneal nerve paralysis and knee instability associated with collateral ligament resection. In the current report, the posterior approach to curettage is introduced in a 55-year-old male with GCTB in the proximal fibula. The approach makes a wide operative field for curettage of GCTB in the proximal fibula without dissecting the peroneal nerve. The approach would prevent postoperative peroneal nerve palsy and knee instability and possibly reduce recurrences.


2019 ◽  
Vol 1 (4) ◽  
Author(s):  
Prisca Oriana Sutanto ◽  
Agus Roy Rusli Hamid ◽  
Adinda Putra Pradhana

Giant cell tumor (GCT) of the distal radius is a rare and unpredictable lesion. The aim of treatment is complete removal of the tumor and preservation of the maximum function of the extremity. Lower rates of local recurrence have been noted after wide resection of the diseased bone. Its standard treatment has ranged from surgical curettage to wide resection. One method for closing the defect is using the head of the fibula as a substitute for the distal radius. The healing of vascularized fibular graft is very quick and without bone resorption. Thus, in the procedure for reconstruction and limb salvage after bone tumor resection of the distal radius, the free vascularized fibular graft with the fibular head is an ideal substitute. This case report will show a patient with GCT that successfully treated by an excision of GCT followed by reconstruction of distal radius using free vascularized fibular graft.


Hand ◽  
2017 ◽  
Vol 12 (5) ◽  
pp. NP113-NP117 ◽  
Author(s):  
Laura W. Lewallen ◽  
Eric R. Wagner ◽  
Steven L. Moran

Background: Giant cell tumor (GCT) of bone is a benign, though locally aggressive tumor, classically described as an eccentric lytic lesion, often with cortical expansion and destruction. It typically involves the metaphysis or epiphysis of long bones in skeletally mature patients, with a slight female predominance. The incidence in the small bones of the hand has been reported to be 2% to 5%. Methods: Treatment options have evolved in recent years, and currently include intralesional curettage with or without adjuvant therapy, wide resection, and occasionally amputation. Results: In this report, we present a long-term follow-up (10 years) of a patient with GCT involving a metacarpal, who was initially reconstructed with a metacarpal head allograft, which was eventually revised to a metacarpophalangeal (MCP) total joint arthroplasty. Conclusions: To our knowledge, this is the only report of pyrocarbon being used for tumor reconstruction and the only report of late MCP allograft salvage.


2018 ◽  
Vol 14 (3) ◽  
pp. 165-167
Author(s):  
Suresh Pandey

ABSTRACTGiant Cell tumor (GCT) is the benign tumor commonly found in second to fourth decade of life. Proximal fibula is very rare site and its occurrence in immature skeleton is still rare with very limited case report. We present a case of painful bony lesion arising from proximal fibula diagnosed as GCT in 15 year boy which was managed successfully with marginal excision and lateral collateral ligament anchorage in proximal tibia. There is no evidence of local recurrence,  lung metastasis, knee pain and instability till 24 months of follow up. Keywords: giant cell tumor; proximal fibula; marginal excision . 


Sign in / Sign up

Export Citation Format

Share Document